Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk

2.

Lymph node transfer reduces arm swelling after breast cancer surgery, study shows

3.

Glioblastoma cells can 'unstick' from their neighbors to become more deadly

4.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

5.

In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot